Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function [Imaging]

ConclusionsIn symptomatic diabetic patients without obstructive coronary artery disease, ranolazine did not change exercise‐stimulated myocardial blood flow or CFR but did modestly improve diastolic function. Patients with more severe baseline impairment in CFR may derive more benefit from ranolazine.Clinical Trial RegistrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01754259.

Source: JAHA:Journal of the American Heart Association - May 4, 2017 Category: Cardiology Authors: Shah, N. R., Cheezum, M. K., Veeranna, V., Horgan, S. J., Taqueti, V. R., Murthy, V. L., Foster, C., Hainer, J., Daniels, K. M., Rivero, J., Shah, A. M., Stone, P. H., Morrow, D. A., Steigner, M. L., Dorbala, S., Blankstein, R., Di Carli, M. F. Tags: Coronary Circulation, Diabetes, Type 2, Nuclear Cardiology and PET Original Research Source Type: research